Novo Nordisk To 'Double Obesity Drug Sales by 2025'

Danish Group Says Year Off To ‘Good Start’

05 May 2021

• By Sten Stovall

Novo Nordisk at its Q1 update lifted full-year guidance and voiced confidence it can double sales of innovative treatments for obesity by 2025.

Group Plans Phase IIIa Oral Semaglutide Obesity Trial Dosed At 50mg • Source: Alamy

More from Earnings

More from Business